Prognostic value of <it>KRAS </it>genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

Prognostic value of <it>KRAS </it>genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

<p>Abstract</p> <p>Background</p> <p>Bevacizumab (BEV) plus triplet chemotherapy can increase efficacy of first-line treatment of metastatic colorectal cancer (MCRC), particularly integrated with secondary liver surgery in liver-limited (L-L) patients. The prognostic va...

Full description

Bibliographic Details
Main Authors: Bruera Gemma, Cannita Katia, Di Giacomo Daniela, Lamy Aude, Troncone Giancarlo, Dal Mas Antonella, Coletti Gino, Frébourg Thierry, Sabourin Jean, Tosi Mario, Ficorella Corrado, Ricevuto Enrico
Format: Article
Language:English
Published: BMC 2012-11-01
Series:BMC Medicine
Subjects:
disease extension
intensive regimen
<it>KRAS </it>mutations
metastatic colorectal cancer
triplet chemotherapy plus bevacizumab
Online Access:http://www.biomedcentral.com/1741-7015/10/135

Internet

http://www.biomedcentral.com/1741-7015/10/135

Similar Items